The one compound here with a real clinical record, which makes it the one where reading the evidence carefully teaches the most.
Every other compound in this section has the same evidential shape: a deep pile of animal work, a handful of small human studies, and a gap between them. Thymosin alpha-1 breaks that pattern completely.
It is approved in more than 35 countries. It has been through over 30 clinical trials with more than 11,000 human subjects. It has a brand name, thymalfasin, sold as Zadaxin.
Which makes it the one compound here where the interesting question is not whether human evidence exists, but what happens when you look closely at the human evidence that does.
It is a 28-residue peptide, cut from a larger precursor called prothymosin alpha, and your own thymus makes it.
That gland sits behind the breastbone, and it is where T cells are trained. Thymosin alpha-1 is the signal it uses to bring immature T cells to maturity.
The thymus starts shrinking after puberty. By your forties and fifties, much of the working tissue has been replaced by fat. That process is called thymic involution, and it is a main reason immunity weakens with age. Fewer new T cells, less effective ones, a slower response to anything unfamiliar. The result is immunosenescence, and it is why older adults get more infections, respond less well to vaccines, and develop more cancers.
That gives the compound an unusually clean rationale. It is not adding a foreign signal. It is topping up one that is running down.
Thymosin alpha-1 is not TB-500, which is thymosin beta-4.
They share a prefix because both were originally pulled from thymus extract. That is the entire connection. One is 28 residues and modulates immunity; the other is 43 residues and moves actin around for tissue repair. Different structures, different jobs.
It flips on the sensors. Immune cells carry Toll-like receptors that detect specific threats. Thymosin alpha-1 activates TLR-2 and TLR-9. That fires two downstream pathways: NF-κB, the master switch for immune gene activation, and IRF3, which drives interferon production. Romani and colleagues established this in Blood in 2004. It pins the mechanism down rather than leaving it as description.
It matures T cells. The core action. More CD4+ helper cells, which direct the response, and more CD8+ killer cells, which destroy infected and abnormal cells.
It reverses exhaustion. Worth pausing on. T cells that have fought too long shut down, and they announce it by displaying markers like PD-1 and Tim-3. Thymosin alpha-1 reduces those markers — restarting cells that had stopped rather than only recruiting new ones.
It wakes up the rest. Natural killer cells, which kill infected and early tumour cells without training. Dendritic cells, which show T cells what to attack, matured via p38 MAPK and NF-κB with more IL-12.
And it raises visibility. It increases MHC class I on cell surfaces. That makes infected and tumour cells show more of what is inside them, which is exactly what CD8+ cells read before they kill. In tumours it also pushes macrophages from the M2 type, which shelters tumours, toward the M1 type, which attacks them.
The marketing line for this compound is that it modulates rather than stimulates: raises a weak immune system, calms an overactive one.
The mechanism does support it. IL-2 and interferon-gamma go up, which is activation. IL-10 goes up too, which is anti-inflammatory. TNF-alpha moves either way depending on context.
Take that as a fair account of the cytokine data. Do not take it as a promise that the compound reads your situation and corrects it. "It adjusts in both directions" is a much easier claim to make than to demonstrate. The autoimmune reports are where it gets tested, and they split: some people report fewer flares, others a worsening first. An immune system recalibrating and an immune system being provoked look identical from the outside.
This is the most instructive thing on the page, and it is not really about sepsis.
The TESTS trial is the largest randomised trial ever run on this compound. It appeared in the BMJ at the start of 2025. Phase 3, double-blind, placebo-controlled, 1,089 adults across 22 centres. Twenty-eight-day mortality was 23.4% on treatment against 24.1% on placebo. No effect.
A 2025 meta-analysis pooled 11 randomised trials and 1,927 patients and found a statistically significant mortality reduction — odds ratio 0.73, confidence interval 0.59 to 0.90. A real result by the usual standards.
Then the authors did the thing that matters. They restricted the analysis to high-quality multicentre trials only.
The benefit disappeared.
That is the whole lesson in one line. The apparent effect was carried by the smaller and weaker studies; the rigorous ones had nothing in them. It is the most common way a compound picks up a reputation it cannot support. You can see it here only because someone ran the sensitivity analysis and published what came back.
Subgroups — septic patients with cancer, diabetes, coronary disease — showed possible benefit at low to moderate credibility. Which is to say: worth another trial, not worth a conclusion.
The honest summary is the source's own: no broad reduction in sepsis mortality, possibly something in specific critically ill groups.
Applying the same scepticism in the other direction, several results hold up better.
Hepatitis B. Mutchnick's 1991 placebo-controlled pilot. Six of seven treated patients cleared HBV DNA, against one of five on placebo, and liver biopsy confirmed it. Lymphocyte, CD3 and CD4 counts improved, with no adverse effects across 26 months of follow-up. Twelve patients in total. Small, but controlled and biopsy-confirmed. Sugahara's 24-week study later showed increased intrahepatic NKT and CD8+ cells, with two of seven normalising liver enzymes and clearing HBV DNA.
Vaccine response in older adults. Gravenstein, 1989, double-blind and placebo-controlled, 90 men aged 65 to 99: antibody response to influenza vaccine was augmented, with no toxicity. A Phase 2 study put influenza incidence at 6% with vaccine plus thymosin alpha-1 against 19% with vaccine alone.
That second one is the closest match between mechanism and outcome anywhere in this section. The compound's premise is that ageing thymic output weakens immune response; the trial measured a weakened immune response in older adults and found it improved.
Cancer adjunct. Reviewed by Costantini in 2019. Improved survival after surgery in liver cancer; longer median survival added to sorafenib; 36 to 50% response rates in melanoma Phase II combinations. The striking figure is in melanoma. Patients given thymosin alpha-1 before ipilimumab reached a median overall survival of 38.4 months, against 8 months on ipilimumab alone. In lung cancer, a meta-analysis of 10 trials and 724 patients found better response and tumour control rates alongside chemotherapy. Always alongside conventional treatment, never instead of it.
COVID-19. Liu's 2020 review of 76 severe cases put mortality at 11.11% treated against 30.00% untreated, with restored T cell counts and reduced exhaustion markers. But it was retrospective, not randomised, and other COVID studies came out mixed. Given what the sepsis data just showed about study quality, this belongs in the suggestive column, not the established one.
Across 11,000-plus subjects the tolerability is genuinely good. Dinetz and Lee's 2024 review found it well tolerated across every studied application, with no serious adverse events pinned on the compound alone. They argued from that record that the FDA should allow compounding. Reported effects are mild: injection site irritation, some fatigue early on, occasional headache or disturbed sleep.
Now the exception, and it deserves emphasis because across six articles in this section almost every interaction note has read "no concerns."
A 2026 case report describes a patient with nasopharyngeal carcinoma given thymosin alpha-1 alongside sintilimab, a PD-1 checkpoint inhibitor: high fever, rash, interstitial pulmonary oedema, multiple organ failure.
The cause was excessive immune activation from stacking two immunostimulatory therapies. Not the peptide alone — the combination. If you are on any cancer immunotherapy, this is not a decision to make without your oncologist.
The mirror-image contraindication is just as firm. Organ transplant recipients on immunosuppression should not use it, because it pushes immunity in exactly the direction those drugs exist to prevent. Same logic for TNF inhibitors like Humira or Enbrel. The compound raises what the biologic is deliberately holding down, so the prescribing doctor has to be part of that conversation.
You will probably not feel anything. No sensation, no energy surge, nothing like a growth hormone peptide. The action is cellular. What shows up is fewer or shorter illnesses over months, and blood work.
The effect does not stick. This is where it differs from everything else in this section. Repaired tissue stays repaired after you stop BPC-157. Here the compound stands in for a gland that is still shrinking. Stop, and the decline picks up where it left off. One reported case tracked white cells, lymphocytes and CD4 counts rising after a short course and returning to baseline within two weeks of stopping. That is exactly what the pharmacology predicts — a two-hour half-life, no accumulation, back to baseline within a day of each dose.
And the thing not to expect: an obvious personal read on whether it is working. The evidence here is infection frequency and lab values over time, not how you feel on a Tuesday.
Worth noting because it runs opposite to everything else covered on this site.
Thymosin alpha-1 went onto the FDA's Category 2 bulk drug substances list in 2023, which shut compounding pharmacies out. In September 2024 it came off that list when the nomination was withdrawn. It is expected to move to Category 1 — compoundable under prescription.
BPC-157, TB-500 and injectable GHK-Cu are all still sitting where this one used to be. This is the only compound in the section moving toward legitimacy rather than away from it, and the 11,000-subject safety record is why.
This article explains published research and the rules around it. It carries no dose, no protocol, and no claim that any compound treats, cures or prevents a condition in anyone. Where the evidence is thin we say so. See our editorial standards.
Research-grade material, sold for laboratory research use. We link to a single supplier rather than a list, so you know exactly where the recommendation goes. Check the certificate of analysis against what a COA can and cannot show before you buy anything.
Commercial link. Nothing on this page is a dose, a protocol, or a claim that this compound treats or prevents any condition.
KLOW is GLOW plus 10 mg of KPV — that part is simple. The more useful fact is that both are, by mass, mostly copper peptide, and that is the ingredient whose injected form has no human trials.
An open study found sleep normalised in six of seven patients. The controlled study by the same investigator found weak effects and said so. The difference between them is a placebo arm.
It does not raise dopamine — it magnifies what other things do to it. That one property explains why caffeine feels stronger on it, and why MAO inhibitors are a hard contraindication.
